Comprehensive medication guide to Mounjaro including estimated pricing, availability information, side effects, and how to find it in stock at your local pharmacy.
Estimated Insurance Pricing
$25–$150/month (with commercial insurance; varies widely by plan and indication)
Estimated Cash Pricing
$550–$1,060/month list price; Eli Lilly savings card can reduce to $25/month for eligible patients
Medfinder Findability Score
60/100
Summarize with AI
On this page
Mounjaro (tirzepatide) is a prescription injectable medication FDA-approved in May 2022 for type 2 diabetes, manufactured by Eli Lilly. It is the first and only dual GIP/GLP-1 receptor agonist.
In clinical trials, Mounjaro achieved average A1C reductions of 2.0–2.3% and weight loss of 15–25 pounds. Up to 50% of patients reached non-diabetic A1C levels.
Its sister drug Zepbound contains the same active ingredient but is approved for weight management.
Medfinder helps you locate pharmacies with Mounjaro in stock.
![Why is Mounjaro so hard to find? [Explained for 2026]](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2Fvur4atr4%2Fproduction%2F4a9a20a1b8a685c9e4315eb3d1aa484d08761479-1408x768.jpg%3Frect%3D0%2C32%2C1408%2C704%26w%3D400%26h%3D200%26auto%3Dformat&w=828&q=75)
We have a 99% success rate finding medications, even during nationwide shortages.
Need this medication?
Mounjaro is a dual GIP/GLP-1 receptor agonist that mimics two hormones involved in blood sugar regulation and appetite control. GLP-1 activation stimulates insulin release and slows gastric emptying. GIP activation enhances these effects and may benefit fat metabolism.
Effects on blood sugar are noticeable within 1–2 weeks, with maximum A1C reduction after 12–24 weeks.
2.5 mg (starting dose)
5 mg
7.5 mg
10 mg
12.5 mg
15 mg (maximum dose)
Mounjaro (tirzepatide) is an injectable medication for type 2 diabetes that has seen unprecedented demand — largely driven by its significant weight loss effects. We've assigned it a findability score of 60 out of 100, meaning patients should expect moderate difficulty locating this medication depending on dose and location.
The FDA officially resolved the tirzepatide shortage in October 2024 and reaffirmed this decision in a December 2024 declaratory order. A federal court upheld the decision in May 2025. All six Mounjaro dose strengths (2.5mg through 15mg) are currently listed as available from Eli Lilly.
However, "resolved" doesn't mean every pharmacy has it on the shelf. The FDA has acknowledged that patients may still experience intermittent localized supply disruptions as the medication moves through the supply chain.
FDA enforcement deadlines for compounded tirzepatide passed in early 2025. An estimated up to 2 million patients were using compounded tirzepatide, many of whom are now transitioning to brand-name Mounjaro or Zepbound — adding pressure on pharmacy supply.
Mounjaro is not a controlled substance, so there are no DEA production quotas or pharmacy stocking limits. The main barriers are insurance coverage, cost, and local pharmacy stocking.
Medfinder can help you find Mounjaro in stock near you.
Mounjaro is not a controlled substance. Endocrinologists, PCPs, obesity medicine specialists, NPs, and PAs can prescribe it. Telehealth prescribing is available.
Medfinder helps you find pharmacies with availability.
No. Automatic refills, 90-day supplies, easy pharmacy transfers, and telehealth prescribing are all possible. The primary barriers are insurance coverage and cost.
Medfinder can help you find Mounjaro near you.
Boxed Warning: Thyroid C-cell tumor risk based on animal studies.
Know what you need? Skip the search.
Ozempic (semaglutide)
Once-weekly injection for type 2 diabetes.
Trulicity (dulaglutide)
Once-weekly injection.
Rybelsus (semaglutide oral)
Daily oral tablet.
Zepbound (tirzepatide)
Same ingredient, approved for weight management.
Wegovy (semaglutide 2.4 mg)
Approved for chronic weight management.
SGLT2 inhibitors
(Jardiance, Farxiga)
Metformin
Prefer Mounjaro? We can find it.
Oral contraceptives
moderateMay reduce effectiveness due to slowed gastric emptying.
Insulin and sulfonylureas
moderateIncreased hypoglycemia risk.
Narrow therapeutic window drugs
moderateWarfarin, levothyroxine, digoxin.
Do not combine with other GLP-1 agonists.
moderateMonitor blood sugar closely during dose changes with other diabetes medications.
moderateMounjaro is a breakthrough for type 2 diabetes as the first dual GIP/GLP-1 receptor agonist. The tirzepatide shortage is officially resolved, and Eli Lilly has massively expanded manufacturing. The main challenge is cost — Eli Lilly's savings card can reduce copays to $25/month for eligible patients.
Medfinder helps you find pharmacies with Mounjaro in stock. Search for availability near you.
Medfinder Editorial Standards
Our medication guides are researched and written to help patients make informed decisions. All content is reviewed for accuracy and updated regularly. Learn more about our standards
ChatGPT
Claude
Perplexity
Grok
Gemini